Superworth

LifeMD price to book ratio LFMD

Market value divided by the book value of the company's net assets, since 2013.

Today, Oct 23, 2026
12.9×
10-year median
14.7×
Against its 10-year history
41st
percentile: 0 is its lowest day, 100 its highest
10-year range
3.0× to 144×
Peer median
1.9×

LifeMD's price to book ratio is 12.9× as of Oct 23, 2026.

That is below its ten-year median of 14.7×, close to the middle of its last ten years.

Over that time it ranged from 3.0× in Apr 2022 to 144× in May 2024.

The median for 10 healthcare stocks of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far12.9×7.2×141×
2025128×118×141×
2024144×110×144×
2023n/m a value too high to mean anything
202218.6×3.0×25.6×
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
201915.1×4.7×19.7×
20185.8×5.4×20.1×
201718.5×18.5×69.5×
201630.1×25.5×121×
2015n/m a value too high to mean anything
2014187×24.6×195×
2013195×29.4×195×

Against its peers

Companies in Healthcare nearest LifeMD's size, closest first, today.

CompanyPrice to book ratio
LFMDLifeMD12.9×
KEQUKewaunee Scientific1.3×
ICCCImmucell3.0×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
APTAlpha Pro Tech0.9×
PDEXPro DEX4.2×
PLXProtalix BioTherapeutics2.9×
NATRNatures Sunshine Products1.3×
ATNMActinium Pharmaceuticals1.6×
ELMDElectromed4.1×
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on LifeMD

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.